Dalgleish, Angus G
Stebbing, Justin
Adamson, Douglas JA
Arif, Seema Safia
Bidoli, Paolo
Chang, David
Cheeseman, Sue
Diaz-Beveridge, Robert
Fernandez-Martos, Carlos
Glynne-Jones, Rob
Granetto, Cristina
Massuti, Bartomeu
McAdam, Karen
McDermott, Raymond
Martín, Andrés J Muñoz
Papamichael, Demetris
Pazo-Cid, Roberto
Vieitez, Jose M
Zaniboni, Alberto
Carroll, Kevin J
Wagle, Shama
Gaya, Andrew
Mudan, Satvinder S
Article History
Received: 31 March 2016
Revised: 22 June 2016
Accepted: 22 July 2016
First Online: 6 September 2016
Competing interests
: Angus G Dalgleish and Andrew Gaya have received travel grants and conference funding from Immodulon Therapeutics. Satvinder Mudan is an unsalaried director and shareholder of Immodulon Therapeutics, Ltd. Robert Glynne-Jones received honoraria and research funding from Merck KgaA, Roche and Sanofi-Aventis. Shama Wagle and Kevin Carroll, of TranScrip, LLP, provided medical writing and statistical support to Immodulon Therapeutics. The remaining authors declare no conflict of interest.